Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated Approved for use through 3/31/2007. OMB 0651-0021 U. S. PATENT AND TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE MC085YP TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5) DESIGNATED/ELECTED OFFICE (DO/EO/US) 0/560672 **CONCERNING A FILING UNDER 35 U.S.C. 371** INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/CA04/000948 28 June 2004 30 June 2003 TITLE OF INVENTION CATHEPSIN CYSTEINE PROTEASE INHIBITORS APPLICANT(S) FOR DO/EO/US Christopher Bayly, Cameron Black, Sheldon Crane, Daniel J. McKay, Renata Oballa and Joel Robichaud Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371. This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected (PCT Article 31). A copy of the International Application as filed [35 U.S.C. 371(c)(2)] a. is attached hereto (required only if not communicated by the International Bureau). b. X has been communicated by the International Bureau. c. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)]. a. is attached hereto has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)]. are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)]. An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)]. 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 [35 U.S.C. 371(c)(5)]. Items 11 to 20 below concern other document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. X A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification.

17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.

A second copy of the English language translation of the international application under 35 U.S.C.154(d)(4).

A second copy of the published International Application under 35 U.S.C.154(d)(4).

Page 1 of 2

16. A power of attorney and/or change of address letter.

Other items or information:

\*\* ~ 1100 AL CIVE 10 Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected Office(DO/EO/US)Concerning a Submission Under

INTERNATIONAL APPLICATION NO. ATTORNEY'S DOCKET NUMBER U.S. APPLICATION NO. (If known, see 37 CFR 1.5) PCT/CA04/000948 MC085YP The following fees are submitted: CALCULATIONS PTO USE ONLY Basic national fee.....\$300 \$300.00 Examination fee (37 CFR 1.492(c)) 22. If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)......\$0 All other situations.....\$200 Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the international preliminary examination report prepared by Search fee [37 CFR 1.445(a)(2)] has been paid on the international application to the USPTO as an \$400.00 International Searching Authority..... International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB ..... All other situations......\$500 TOTAL OF 21, 22 and 23= \$700.00 Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof. Number of each additional 50 or fraction Total Sheets Extra Sheets RATE thereof (round up to a whole number) -100 =0 /50  $\mathbf{X}$ \$250.00 \$0.00 Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date [37 CFR 1.492(e)]. CLAIMS NUMBER FILED NUMBER EXTRA RATE Total Claims - 20 = 0 х \$0.00 11 \$50.00 Independent Claims X \$200.00 \$0.00 -3 =0 MULTIPLE DEPENDENT CLAIM(S) (if applicable) \$360.00 TOTAL OF ABOVE CALCULATIONS (SUBTOTAL) \$700.00 Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)). = \$700.00 TOTAL NATIONAL FEE Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).\$40.00 per property. TOTAL FEES ENCLOSED = \$700.00 Amount to be refunded: Amount to be charged: A check in the amount of \$ \_\_\_\_\_ to cover the above fees is enclosed. Please charge my Deposit Account No. 13-2755 in the amount of \$700.00 to cover the above fees. b. A duplicate copy of this sheet is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to the Deposit Account No. 13-2755. A duplicate copy of this sheet is enclosed. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the International Application to pending status. SEND ALL CORRESPONDENCE TO: Customer No. 000210 colembreller MERCK & CO., INC. Patent Department, RY60-30 P.O. Box 2000 126 East Lincoln Avenue Rahway, New Jersey 07065-0970 Nicole M. Beeler **NAME** DATE: December 14, 2005 <u>45,194</u> PHONE #: (732) 594-1077 **REGISTRATION NUMBER** 

Approved for use through 3/31/2007. OMB 0651-0021

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected Office(DO/EO/US)Concerning a Submission Under 35 U.S.C. 371" Approved for use ;hrough 3/31/2007. OMB 0651-0021

## 10/560672 IAPO Rec'd PCT/PTO 14 DEC 2009

## Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

Attorney Docket No.:	MC085YP
International Appln No.:	PCT/CA04/000948
International Filing Date:	28 June 2004
Priority Date:	30 June 2003
Title:	CATHEPSIN CYSTEINE PROTEASE INHIBITORS
Inventors:	Christopher Bayly, Cameron Black, Sheldon Crane, Daniel J. McKay, Renata Oballa and Joel Robichaud

EVENECO MAIN GERTIFICATE
EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT December 14, 2005
EXPRESS MAIL NO. EL 989590521 US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS
EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR
PATENTS P.Q. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.
La Cilia
MAILED BY () () (DATE December 14, 2005